Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Mycosis Fungoides Clinical Trials

A listing of Mycosis Fungoides medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (39) clinical trials

The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with MF-CTCL who are receiving therapy with Valchlor. Patients will be followed prospectively for a maximum of 1 year from the date of signed informed consent (enrollment) until end of study. Continuation in the ...

Phase N/A

To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides). Other Details: HPN-CTCL-01

Phase

People with Lymphoma and Leukemia are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

PRIMARY OBJECTIVES: I. To assess the clinical benefit of nivolumab in T-cell lymphomas, as measured by objective response rate (ORR) within 12 cycles according to the Lugano Classification Response Criteria (2014). SECONDARY OBJECTIVES: I. To assess safety and tolerability of the regimen in this patient population. II. To assess progression-free ...

Phase

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Primary Objective To determine overall response rate (CR+PR) of brentuximab vedotin in CD30 low (<10%) relapsed or refractory T cell lymphoma (TCL) Secondary Objective(s) Complete remission (CR) rate Duration of response (DOR) Progression free survival (PFS) Overall survival (OS) Time to treatment failure (TTF)

Phase

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (recommended phase 2 dose, RP2D) of lenalidomide, when given in combination with fixed-dose durvalumab. (Phase 1) II. To assess the safety and tolerability of the lenalidomide/durvalumab regimen, and accompanying dose modification plan, by evaluation of toxicities including: type, frequency, severity, attribution, ...

Phase

Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

The aim of this study is to evaluate the efficacy of doxycycline in relapsed Cutaneous T-cell Lymphomas (CTCL). The primary objective is to determine the overall response rate of doxycycline monotherapy in patients with relapsed CTCL.

Phase

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

This is a multicenter, open-label, phase 1 study that is being done to test intratumoral injections of TTI-621 in patients that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts: Dose Escalation and Dose Expansion. During the escalation part ...

Phase

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Hodgkin Lymphoma or Stage IV Breast Cancer

PRIMARY OBJECTIVES: I. To assess the safety of in vivo in host drug sensitivity testing in patients with breast cancer and patients with lymphoma (nodal, extranodal or cutaneous lesions). SECONDARY OBJECTIVES: I. To assess the feasibility of in vivo in host drug sensitivity testing in this patient population. II. To ...

Phase

Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides

Objectives Objective is to evaluate the efficacy of doxycycline in treatment of early stages of mycosis fungoides (IA, IB and IIA) and to assess its apoptotic enhancing effect by studying the expression of BCL2 by the T lymphocytes. Study Design Randomized controlled trial Population of study & disease condition 30 ...

Phase